IMPORTANCE Infection with JC virus (JCV) may lead to development of demyelinating progressive multifocal leukoencephalopathy in patients with multiple sclerosis (MS) who are treated with natalizumab.
INTERVENTIONS Natalizumab treatment of MS.

MAIN OUTCOMES AND MEASURES
The blood samples were separated using flow cytometry into CD34 S ince the reintroduction of natalizumab therapy in 2006 for relapsing remitting forms of multiple sclerosis (MS), more than 440 cases of progressive multifocal leukoencephalopathy (PML), the central nervous system virusinduced demyelinating disease, have been reported. The highest incidence of PML is approximately 1:80 in patients with a combination of risk factors, including receiving 24 or more natalizumab infusions, a history of immunosuppressive treatment, and seropositivity for antibodies to the JC virus (JCV). The overall incidence of PML in natalizumab-treated MS patients is 1:250, with approximately 11 new cases reported each month. 1, 2 Several hypotheses have focused on the direct association of natalizumab treatment and PML, particularly because few other opportunistic infections occur in this group. 3 One putative mechanism centers on the lack of immune surveillance in the central nervous system because natalizumab blocks extravasation of T and B lymphocytes into the brain. 4 This concept is predicated on the presence of JCV in the brain in a latent or persistent state of residency so that, at times of protracted immune suppression, a productive amplification of viral infection is established. Although this concept may be partly true, it does not explain why PML has not been reported in MS patients treated with a variety of other immunosuppressive agents (eg, azathioprine, mycophenolate, mitoxantrone hydrochloride, and rituximab). However, if protracted immune suppression was the primary mechanism of PML in such patients, we would anticipate PML occurring in MS patients whose immune systems are more severely compromised than seen in natalizumab-treated patients. Further, JCV infection in the brains of MS patients not treated with natalizumab has not been reported. The only reports of PML in MS patients are those treated with natalizumab.
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Another proposed mechanism to explain the unique link between natalizumab treatment and PML is the drug's effect on the mobilization of mononuclear cells from the bone marrow, 6 ,7 some of which may harbor latent JCV infection. [8] [9] [10] These observations are not mutually exclusive, however, and may actually work in concert to provide the circumstances in which 2 very different demyelinating diseases can occur in the brain of a single patient. To investigate the link between natalizumab treatment and the presence of JCV in lymphoid cells, peripheral blood samples were collected from MS patients before the first dose of natalizumab, on the day treatment was initiated, and periodically during the course of the next 10 monthly infusions. Blood samples were also collected at a single point from MS patients who received at least 24 infusions and from healthy volunteers who were matched by age and sex to the natalizumabtreated MS patients. 
Methods
Patients
Flow Cytometric Analysis
Cells were analyzed using a flow cytometer (FACSAria II SORP; BD Biosciences) equipped for the detection of as many as 6 fluorescence variables. Events collected for each sample numbered from 5000 to 50 000. 
Quantitative Polymerase Chain Reaction for JCV Genome
Cell samples were examined using the validated, Clinical Laboratory Improvement Amendment-certified JCV quantitative polymerase chain reaction (PCR) method. 11-13 Cellular DNA was extracted from a maximum of 5.0 × 10 6 cells per sample using a DNA blood and tissue kit (DNeasy, catalogue No. 69504; Qiagen) and eluted to a final volume of 25 μL. The primers and probes for the specific amplification and detection of the conserved N-terminal of the JCV T protein do not amplify BK virus or simian virus 40 DNA in this region. Extracted DNA templates were amplified using the PCR reagents (TaqMan Universal reagent, catalogue No. 4304437; Applied Biosystems) and a commercially available PCR system (7500 Real-Time System; Applied Biosystems). All samples were run in duplicate using 10 μL per reaction. The number of JCV genomes was calculated using the manufacturer's system software and adjusted according to the dilution factors before reporting as copies per milliliter only when both duplicates detected viral DNA.
Enzyme-Linked Immunosorbent Assay for Determination of Anti-JCV Antibody
The gene that codes for the major JCV structural protein, Vp-1, was amplified from SVG cells 14 infected with the Mad-4 viral variant of persistently infected owl monkey 586 tumor cells. 15 This amplified VP1 gene was ligated into the pBlueBacIII plasmid vector and cotransfected into Sf9 insect cells along with the baculovirus DNA expression vector system (BAc-N-Blue; Invitrogen) according to the manufacturer's protocol. Subsequent proliferating baculovirus expressing the recombinant Vp-1 was used as the inoculum in Sf9 expansion cultures. Supernatant from the expansion cultures was ultracentrifuged through 40% (weight to volume ratio) sucrose cushions. The resulting recombinant Vp-1 pellets were subjected to deoxycholic acid treatment, low protein-binding polyethersulfone membrane filtration, and gradient banding on density gradient medium (OptiPrep; Nycomed) to remove cell lysate contaminants. This highly purified recombinant Vp-1 was used as the antigen in establishing the enzyme-linked immunosorbent assay (ELISA) for determining the level of JCV antibody response present in the clinical samples. In the ELISA, 4× serial dilutions that generated an optical density reading of 0.05 greater than that of plate and well controls were labeled as positive at a dilution of 2560. The highest dilution of a sample registering positive findings was used to identify the titer of the sample. 16 We compared the LMMN ELISA assay directly with a second-generation JCV antibody ELISA (STRATIFY JCV; Focus Diagnostics) supplied as a kit by the manufacturer using 17 plasma samples from these patients. Fifteen of the 17 samples showed identical serological results, whereas 2 other samples that the LMMN ELISA showed to have seronegative results had indeterminate results using the STRATIFY JCV ELISA after step 2 adsorption with viruslike particles as described below.
Results
Natalizumab is known to promote mobilization of hematopoietic stem cells from the bone marrow, a putative site for JCV latency, into the peripheral circulation, resulting in higher-thannormal physiological levels of CD34 + cells for months to years after treatment. Therefore, we collected blood samples and separated them into CD34 compared with healthy volunteers (Figure 2) as in previous observations. 17 Percentages of CD34 + and CD19 + cells were persistently elevated in the blood samples from MS patients treated with natalizumab starting at 3 months and for extended periods. Although all blood samples were separated into cell compartments by flow cytometry, the data in Table 1 report only those samples confirmed to harbor detectable levels of JCV DNA. Patients described in Table 1 reflect the acquisition of the samples that were sent to the LMMN for analysis and not the total number of patients in either cohort. Blood samples were collected at baseline (before infusion) and at approximately 3-month intervals to 9 or 10 months, depending on patient status, for the 26 patients initiating treatment. A total of 92 samples from this cohort (4 samples of 120 mL each) underwent analysis. Table 1 shows the study participants with viremia, the specific compartment in which viremia was detected, the number of infusions, and the antibody titer of the plasma at the time of testing. Antibody titers of 2560 or greater are considered seropositive. and CD19 + cells in 1 of these patients. Regardless of the compartment in which viral DNA was detected across all 3 groups, the copy number of viral genomes was low, particularly when compared with the numbers usually seen in virus excreted into the urine, or viruria. None of the samples from any group had detectable viral DNA in the CD3 + T cells, the cell control from each patient irrespective of group designation. JC virus has not been shown to bind to or infect T cells. 19 When both patient groups were combined ( Table 2) , 15 of 49 patients (31%) were viremic in CD34 + cells at different times, including 2 patients at baseline with a mean of 25 copies/mL in the initiating group and 212 copies/mL in the longer treatment group. Twelve of the 49 patients (24%) were viremic in CD19 + cells, with a mean of 96 copies/mL in the initiating group and 543 copies/mL in the longer treatment group. The plasma viremia in these patients has been reported previously. 18 Seventeen patients (35%) had plasma viremia. Six patients were viremic only in the plasma (patients 3, 8, 10, 33, 36, and 48), including 4 at baseline with a mean of 86 copies/mL in the initiating group and 67 copies/mL in the longer treatment group. Three patients were found to be viremic in all 3 compartments (patients 2, 13, and 40). The high copy number in cell compartments in patient 40, who had 30 infusions, was much larger than those of the others. In general, however, the viral copy number was higher in the longer treatment group, with a mean of 230 copies/mL compared with 71 copies/mL in the initiating group. Analysis of viremia in the longer treatment group showed that viral DNA was primarily localized within CD34 + cells at a mean of 212 copies/mL compared with 25 copies/mL in the initiating group and within CD19 + cells at a mean of 543 copies/mL in the longer treatment group compared with 96 copies/mL in the initiating treatment group. Twenty-nine of 49 patients (59%) had viremia in 1 or more compartments. The serological analysis revealed that 14 of 23 patients (61%) with cell-associated viremia from both groups had seronegative test results using the LMMN ELISA assay. To ensure that these results were not assay dependent, we compared the STRATIFY JCV test kit sent to the LMMN and the LMMN ELISA using the 17 plasma samples previously reported. 18 Both assays showed very similar results. All 11 seropositive samples had the same test results in both assays. Four of the 6 seronegative samples were seronegative in both assays. Two other seronegative samples in the LMMN ELISA would be classified as indeterminate in the STRATIFY JCV assay. The observation that the seronegative individuals can be viremic in cell compartments in this study raises the possibility that lymphoid cell-associated JCV can occur in a persistent state that may not be adequate for antigen presentation and the generation of a humoral immune response.
Discussion
Natalizumab exerts highly significant attenuation of clinical and radiographic features of measures of MS disease activity. However, as a selective adhesion molecule inhibitor, natalizumab also prevents homing of hematopoietic CD34 + stem cells in the bone marrow, consequently augmenting their mobilization into the peripheral circulation. In previous reports, analysis of cell populations in the peripheral blood of MS patients at initiation and then in the first several months of natalizumab treatment showed an increase in CD34 + cells but also in the clonal frequency of circulating B cells. [20] [21] [22] Levels of CD20 + and B cells increased at 6 and 12 months with reduced levels of CD49d, the α 4 integrin, and CD29, the β 1 integrin, both targeted by natalizumab. Immature B cells that can induce interleukin 10 expression 21 are also increased. In another study, 22 natalizumab treatment increased a selective release of bone marrow lymphoid precursors compared with myeloid precursors, resulting in chronic increases in T-and B-cell populations in the peripheral circulation. Marginal zone-like memory B cells significantly increased expression of CD49d, which enables harboring in marginal zones in lymph nodes. Together these studies provide evidence that supports the role of these cell populations as possible disseminators of JCV because natalizumab triggers the mobilization of cells potentially infected with JCV into the circulation. The cell populations described in the present study showed the same pattern of responses with natalizumab treatment, a finding that persisted for several years ( Figure 2 ). The observation of JCV latency within these characterized mononuclear cells makes a direct mechanistic link between natalizumab and the occurrence of PML. We used the highly sensitive, specific, and validated quantitative PCR assay that provided the laboratory confirmation of PML diagnosis in nearly half of the MS cases in the present study to detect viral DNA in cell compartments. 9, 10 in these lymphoid stem cells. The assays that did not detect JCV DNA in similar cell populations probably were not sensi- and 150-mL blood samples that were collected and processed within 24 hours, in contrast to the 18-mL samples used in the other reported study. 25 In addition, the low viral copy number in our study is consistent with a latent or a persistent infection. In previous work, 27,28 a cell culture model had shown that even a low level of persistence of JCV has significance because JCV can be transferred to other cells. In fact, JCV was first isolated by a similar blind passage in human fetal brain cells. 29 Another important observation from our study is the identification of individuals with seronegative test findings but who were nevertheless viremic for JCV ( Table 1 ). The ELISA used in the LMMN is validated using a 4-fold serial dilution of plasma with a cutoff titer of 640 or less, constituting seronegative status. Several samples had titers of 160, an unambiguous seronegative result. Of particular interest are patients 9 and 13, who are seronegative and viremic. In a separate analysis, 30 both of these patients demonstrated T-cell responses to JCV proteins, indicating cell-mediated immune responses to JCV infection. These observations add to the complexity of finding a rigorous set of criteria for identifying patients at increased risk for PML when receiving natalizumab or similar therapies that modulate the immune system.
Although viral serology plays an important role in risk stratification algorithms, 31 the use of serology alone may not be sufficient to identify all patients with prior exposure to JCV. 32 Other measures of JCV infection may be of equal importance and should be considered, including T-cell responses, a rise in antibody titer indicating active infection, and the presence of JCV DNA variants in peripheral circulation, particularly in cell compartments. 33 These additional factors, previously suggested, 18, 34 could be helpful during periodic surveillance if included in stratification protocols. 35 Continued studies seem warranted on the pathoetiologic factors that influence the development of PML in patients treated with natalizumab and other biological modulators of the human immune system.
Conclusions
We detected JCV DNA within the cell compartments of natalizumab-treated MS patients after treatment inception and after 24 months. The JCV DNA may harbor in CD34 + cells in bone marrow that mobilize into the peripheral circulation at high concentrations. Cells with latent infection initiate differentiation to CD19 + cells that favors growth of JCV. Continued studies are needed to further investigate natalizumab treatment as the mechanism of PML. 
